Relapsing Remitting Multiple Sclerosis: Clinical Trials

1 trial for Relapsing Remitting Multiple Sclerosis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 unknown. 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 21Unknown 1

Follow Relapsing Remitting Multiple Sclerosis: new trials by email Literature Review of Relapsing Remitting Multiple Sclerosis trials Research Report on Relapsing Remitting Multiple Sclerosis

Trials (filtered) newest first · largest first

All 1 trial

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Phase 2 Study of Orelabrutinib in Patients With Relapsing-Remitting Multiple Sclerosis
placebo, orelabrutinib - Relapsing Remitting Multiple Sclerosis
Phase 2UnknownBeijing InnoCare Pharma Tech Co., Ltd.1602021-03-012023-04-21

Narrower conditions

Multiple Sclerosis, Relapsing-Remitting (1)

Broader conditions

Autoimmune Diseases (1)  ·  Autoimmune Diseases of the Nervous System (1)  ·  Demyelinating Autoimmune Diseases, CNS (1)  ·  Demyelinating Diseases (1)  ·  Immune System Diseases (1)  ·  Multiple Sclerosis (1)  ·  Nervous System Diseases (1)

Interventions

orelabrutinib (1)

Sponsors

Beijing InnoCare Pharma Tech Co., Ltd. (1)

Countries

China (1)  ·  Poland (1)  ·  Ukraine (1)  ·  United States (1)